Results 121 to 130 of about 15,879 (168)

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis. [PDF]

Prostate
Garcia de Herreros M, Rodrigo C, Ferrer-Mileo L, Fernández-Mañas L, Mases J, Diaz N, Vilaseca A, Altamirano M, Gibanel R, Ribal MJ, Jimenez N, Reig O, Figols M, Climent MÁ, Font A, Mellado B.   +15 more
europepmc   +1 more source

Quantitative PSMA PET Biomarkers for Predicting Response to ¹⁷⁷Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis. [PDF]

J Nucl Med
Kiani I, Siri MA, Babaei M, Aliasghari MM, Mohammadzadeh S, Mohammadi S, Salavati A.   +6 more
europepmc   +1 more source

TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies. [PDF]

Mol Cancer Ther
Hoshi-Kadonosawa Y, Reinhold WC, Taniyama D, Inoue Y, Luna A, Kumar S, Sun NY, Kim YS, Yin JJ, Roper N, Sowalsky AG, Figg WD, Takebe N, Pommier Y.   +13 more
europepmc   +1 more source

Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone. [PDF]

Medicina (Kaunas)
Kaya BE, Koçak MZ, Yıldız O, Aykut T, Gürbüz AF, Genç Ö, Karakurt Eryılmaz M, Araz M, Artaç M.   +8 more
europepmc   +1 more source

Rewriting the cancer proteome: targeting selective translation as a therapeutic frontier. [PDF]

J Clin Invest
Ruggero D.
europepmc   +1 more source

Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases. [PDF]

World J Urol
Wenzel M, Lauer B, Mühlthaler VG, Filzmayer M, Siech C, Le C, Humke C, Kosiba M, Kriegmair M, Steuber T, Chun FKH, Mandel P.   +11 more
europepmc   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source

Prognostic Value of Cycle 1 SPECT SUV_mean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617. [PDF]

J Nucl Med
Ghodsi A, Demirci RA, Gulati R, Nelson PS, Raychaudhuri R, Cheng HH, Sunkara R, Khan H, Rios RN, Hsieh A, Grivas P, Montgomery B, Yezefski TA, Yu EY, Schweizer MT, Chen DL, Iravani A.   +16 more
europepmc   +1 more source

Combined [ 223 Ra]Radiumdichloride and [ 177 Lu]Lu-PSMA-617 Therapy in End-stage Metastatic Castration-resistant Prostate Cancer. [PDF]

Clin Nucl Med
Hügle MJ, Patt M, Dierks A, Steinestel J, Lapa C.   +4 more
europepmc   +1 more source

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. [PDF]

Signal Transduct Target Ther
Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG.   +18 more
europepmc   +1 more source